Clinical trialNACompleted
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004
- Outcome
- Finished, no results posted
- Phase
- NA
- Status
- Completed
- Study type
- Interventional
- Start
- February 2012
- Expected end
- December 2017
- Enrollment
- 274 participants
- Sites
- 1
- Primary outcomes
- Biomarkers
- Sponsor
- Other
- Results posted
- No
- Last update
- 21 April 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat. Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month. The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response. This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.
Papers 10
- Registry-listed results paperInhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. DOI 10.1002/cac2.12365↗
- Registry-listed results paperLimitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. DOI 10.1002/cac2.12335↗
- Registry-listed results paperDNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive … DOI 10.3390/cancers13246354↗
- Registry-listed results paperDesign of Inhibitors of the Intrinsically Disordered Protein NUPR1: Balance between Drug Affinity and Target Function. DOI 10.3390/biom11101453↗
- Registry-listed results paperA glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. DOI 10.1016/j.ebiom.2021.103541↗
- Registry-listed results paperTNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. DOI 10.1038/s41419-021-03920-4↗
- Registry-listed results paperExploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. DOI 10.3390/cancers13102473↗
- Registry-listed results paperA transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
- Registry-listed results paperPancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). DOI 10.3389/fonc.2019.00475↗
- Registry-listed results paperPrognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcin… DOI 10.1080/2162402x.2018.1561120↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.